Further validation of the putative role for POLE, and to a lesser extent POLD1, mutations in endometrial cancer has been obtained from an analysis of unpublished TCGA genomic data, where 21 (8.5%) and 1 (0.4%) tumors out of 248 samples were found to harbor POLE and POLD1 mutations, respectively, including 8 cases of P286R and 5 cases of V411L changes in POLE [60]. The gene discussed is POLD1; the disease is endometrial cancer.